Nilotinib (AMN-107)

For research use only. Not for use in humans.

製品コードS1033

Nilotinib (AMN-107)化学構造

分子量(MW):529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 17100 あり
JPY 13600 あり
JPY 36800 あり
JPY 80000 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(78)

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

製品説明 Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
特性 A selective inhibitor of native and mutant Bcr-Abl.
ターゲット
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
体外試験

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NY\5bXpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTkfo9KSzVyPUCuNFAxOTR2IN88US=> NXHF[I9pW0GQR1XS
KU812 NYrvXZBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorPTWM2OD1yLkCwNlQ5KM7:TR?= M1H3XnNCVkeHUh?=
EM-2 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXJUpJKSzVyPUCuNFA1OSEQvF2= MmrJV2FPT0WU
LAMA-84 NF25N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi5[5VKSzVyPUCuNFA1QSEQvF2= NXzSZYdUW0GQR1XS
MEG-01 NGTKSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEC4Nlgh|ryP NVTJOpVsW0GQR1XS
BV-173 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDNXmlSUUN3ME2wMlAyODh7IN88US=> M3jtdHNCVkeHUh?=
KASUMI-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXQTWM2OD1yLkCyOFE{KM7:TR?= NIH5Z2lUSU6JRWK=
NB7 NV7hPJg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH2W3lKSzVyPUCuNVM1OzlizszN NGHv[3dUSU6JRWK=
BHT-101 M{m0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjLSlNXUUN3ME2wMlY1OjZ|IN88US=> NFS2cotUSU6JRWK=
CGTH-W-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLUcpJQUUN3ME2wMlY1QDdizszN NEPyNlNUSU6JRWK=
HMV-II MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPSdWxKSzVyPUCuO|Q5PzRizszN MnzMV2FPT0WU
NKM-1 NXj5dmhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Kd2tKSzVyPUCuPVAyPSEQvF2= M2DiSHNCVkeHUh?=
LB2241-RCC M3vM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwMEKyNlgh|ryP MV;TRW5ITVJ?
NCI-H1703 NYLCS5B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P3d2lEPTB;MT6xPFg4KM7:TR?= M4\QTnNCVkeHUh?=
BE-13 NVrWR2pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjtc4g6UUN3ME2xMlI4PDF4IN88US=> NEHRWGVUSU6JRWK=
ACN NH7xNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojtTWM2OD1zLkW1NFc4KM7:TR?= M{XjZXNCVkeHUh?=
A204 NW\ucGJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwNUeyNFUh|ryP M2PHS3NCVkeHUh?=
HOP-62 NE\WN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPSUYVqUUN3ME2xMlgzODd5IN88US=> M3TYWHNCVkeHUh?=
H9 NEnpVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;ZTWM2OD1{LkezO|k{KM7:TR?= M2nzbnNCVkeHUh?=
HCC1806 Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TjT2lEPTB;Mj63OFMzPyEQvF2= M1vVW3NCVkeHUh?=
NOS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn3O4w3UUN3ME2yMlg4OTB{IN88US=> M2[0SHNCVkeHUh?=
RS4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr3NHdOUUN3ME2yMlkxPjJ|IN88US=> NHPJUXRUSU6JRWK=
JAR MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTTN48xUUN3ME2yMlkzODh2IN88US=> NX;mem5kW0GQR1XS
T98G M2DmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D1SmlEPTB;Mz6wNVMyOyEQvF2= NHjTXGpUSU6JRWK=
NCI-SNU-1 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TJdGlEPTB;Mz60NFA6OiEQvF2= Mk\VV2FPT0WU
SK-MEL-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rMN2lEPTB;Mz60N|AzQSEQvF2= MVLTRW5ITVJ?
L-363 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nRRWlEPTB;Mz62NVExPyEQvF2= NVLGRVZ4W0GQR1XS
SW982 M{C5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq2Tmx6UUN3ME2zMlY1OTZ7IN88US=> MkG0V2FPT0WU
HT-1080 NF3z[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXuXYlzUUN3ME2zMlkyPzd3IN88US=> M3nVTnNCVkeHUh?=
G-402 NWnZ[IhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP0[pVDUUN3ME20MlMyOjB|IN88US=> M1mzNXNCVkeHUh?=
HOS MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG1c|c{UUN3ME20MlgxOjh{IN88US=> Ml7RV2FPT0WU
SK-NEP-1 M2\sPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTRwOEOxPVEh|ryP NFLWO3BUSU6JRWK=
HAL-01 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X2XGlEPTB;ND64PFI1OiEQvF2= NFHkbYVUSU6JRWK=
SBC-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTRwOUC5NFch|ryP Mor1V2FPT0WU
CTV-1 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPuTWM2OD13LkS4PVM5KM7:TR?= MVTTRW5ITVJ?
LCLC-103H MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTVwN{e0O|Eh|ryP MXXTRW5ITVJ?
RVH-421 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe0T4drUUN3ME21Mlc4PTN4IN88US=> MnHxV2FPT0WU
K-562 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTVwOUCzOkDPxE1? NXfNSZN7W0GQR1XS
CAL-33 NE\scGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj6VW5KSzVyPU[uN|E{PTlizszN NUDPbY1MW0GQR1XS
MDA-MB-361 M1n1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TyN2lEPTB;Nj6zN|Y6QSEQvF2= MYTTRW5ITVJ?
IGROV-1 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W1WmlEPTB;Nj60O|E6OSEQvF2= MVzTRW5ITVJ?
NY Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG1TWM2OD14LkWzOVk6KM7:TR?= NWjzcHpJW0GQR1XS
Ramos-2G6-4C10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjOUXZKSzVyPU[uOlY6OzFizszN MoHvV2FPT0WU
HuO9 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\se2lEPTB;Nj63N|k3PCEQvF2= NIrKVoxUSU6JRWK=
MS-1 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHJdXdKSzVyPUeuNVE6PTNizszN NGG1XZJUSU6JRWK=
RPMI-8226 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrnTWM2OD15LkK4Nlg4KM7:TR?= NX\BUppSW0GQR1XS
HDLM-2 M3nuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW3V5lKSzVyPUeuOFAyPDlizszN NH\nUYdUSU6JRWK=
D-566MG NILqOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLpTWM2OD15LkS3NVU2KM7:TR?= MnPJV2FPT0WU
SK-MEL-24 NIj3ZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTXeFZXUUN3ME23MlY{Ozl{IN88US=> NWfaUIptW0GQR1XS
COLO-679 M{DBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGzTWM2OD15Lkm4OlcyKM7:TR?= MWfTRW5ITVJ?
EW-13 NV7CdlVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfqb4hUUUN3ME24MlMzODV2IN88US=> M1LRWHNCVkeHUh?=
A388 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hv[2lEPTB;OD6zPFQ5OSEQvF2= NUn0ZW4xW0GQR1XS
UM-UC-3 NVfQcml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7obXJ7UUN3ME24MlQ{QTV4IN88US=> NIHnZYxUSU6JRWK=
NUGC-3 M{HiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;TTWM2OD16LkWzOVgzKM7:TR?= M4Dx[HNCVkeHUh?=
COLO-668 NYXQTY5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj3TWM2OD16LkW5OFkyKM7:TR?= MmDaV2FPT0WU
MOLT-4 NXrBUmhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRThwNkKzOVMh|ryP NVnJW3VRW0GQR1XS
D-423MG NYjjdGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\seWVKSzVyPUiuPFM4PTZizszN NVPLeIxzW0GQR1XS
CTB-1 NYXNcYlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRThwOEexNlgh|ryP NGnTUVRUSU6JRWK=
BCPAP NEDwS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEThbo1KSzVyPUmuNFI2PjJizszN NHH4VGVUSU6JRWK=
GCT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nVU2lEPTB;OT6wPVg{OSEQvF2= Ml\GV2FPT0WU
ACHN MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInOSVdKSzVyPUmuNlM3OzJizszN Mnq0V2FPT0WU
KYSE-520 NYC3NXh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[xSWlEPTB;OT6zN|Q5OiEQvF2= MYfTRW5ITVJ?
LB771-HNC NVLObopZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSzSpZRUUN3ME25Mlc3PDl5IN88US=> M2q5VHNCVkeHUh?=
MLMA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LCS2lEPTB;MUCuNFE{OiEQvF2= NFLUV|RUSU6JRWK=
HEC-1 NXPPUpM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqxdY12UUN3ME2xNE4zQDB2IN88US=> MnjWV2FPT0WU
HL-60 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\DW2pFUUN3ME2xNE43QDV|IN88US=> NUK2TFlsW0GQR1XS
A101D M1PVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL6elhIUUN3ME2xNE45QTJ|IN88US=> M4DHTnNCVkeHUh?=
A2058 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\rTWM2OD1zMD65NlQ2KM7:TR?= MmjxV2FPT0WU
KARPAS-45 NVvjO3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M364N2lEPTB;MUGuNFY{PSEQvF2= M3K4UHNCVkeHUh?=
697 NGXZOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHeydIFKSzVyPUGxMlIyODFizszN M3XNenNCVkeHUh?=
NCI-N87 NFXY[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv5RXQzUUN3ME2xNU44PzNzIN88US=> M2LPW3NCVkeHUh?=
DSH1 NUDpUHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\4TWM2OD1zMT63PVU{KM7:TR?= MoLoV2FPT0WU
HLE MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLrTWM2OD1zMT64PFM6KM7:TR?= Ml36V2FPT0WU
NCI-H720 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF{Lk[4NFEh|ryP M3jSZnNCVkeHUh?=
EW-3 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLOTWM2OD1zMj65N|A4KM7:TR?= NIHIU4hUSU6JRWK=
AGS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:zSI83UUN3ME2xN{4xOzVzIN88US=> MnntV2FPT0WU
ES5 NVzOO2h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF|LkC1NVIh|ryP M1voXHNCVkeHUh?=
DB NGXPU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXkTWM2OD1zMz6zNlU3KM7:TR?= MVvTRW5ITVJ?
A4-Fuk NX7pS29oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\XVpRKSzVyPUGzMlQyODJizszN MWnTRW5ITVJ?
A427 M2Tvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH74UmpKSzVyPUGzMlQ6PzJizszN M3LafXNCVkeHUh?=
MN-60 NWrRXo5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvxenpKSzVyPUGzMlU5PDNizszN MlrCV2FPT0WU
HCC2218 NWrNcFB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF|LkW4OVYh|ryP NY[4UYg1W0GQR1XS
MV-4-11 NFvubXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:3TmtKSzVyPUGzMlgyOzdizszN NGOxWIpUSU6JRWK=
GI-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnQeHl1UUN3ME2xOE4yOTh2IN88US=> Ml;MV2FPT0WU
JVM-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPJTWM2OD1zND6yOlU3KM7:TR?= MYjTRW5ITVJ?
NCI-H2029 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF2LkK3Nlch|ryP NHW2TYRUSU6JRWK=
TE-12 NUjrUVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XkeWlEPTB;MUSuOlA1PiEQvF2= MYDTRW5ITVJ?
WM-115 NH3pXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zXVGlEPTB;MUWuOVY5OyEQvF2= MV\TRW5ITVJ?
BB65-RCC NXW5V4RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HGfGlEPTB;MU[uNFI1OSEQvF2= MnXwV2FPT0WU
NCI-H1693 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH0[GJWUUN3ME2xOk4{QDB{IN88US=> M4L5UHNCVkeHUh?=
KARPAS-299 NFrnTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSyWJpwUUN3ME2xOk43OjB|IN88US=> MUDTRW5ITVJ?
UACC-257 M1u1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3Pd5FKSzVyPUG3MlA2QDJizszN MUfTRW5ITVJ?
RKO NE\2ZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHkepNwUUN3ME2xO{43PDN|IN88US=> M{fjeHNCVkeHUh?=
HT-29 NWXNUFAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[xc3ZKSzVyPUG3Mlc5QDlizszN MWXTRW5ITVJ?
ES7 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF6LkGxNlIh|ryP NIPTb|ZUSU6JRWK=
DEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XyVmlEPTB;MUiuN|E4OiEQvF2= MnTIV2FPT0WU
BT-549 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHoTWM2OD1zOD60NFkzKM7:TR?= NHzvRWFUSU6JRWK=
NCI-H1755 NXrMOHF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPvTWM2OD1zOD61O|I{KM7:TR?= NX3QbmtjW0GQR1XS
HCE-T MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDXTWM2OD1zOD64N|QyKM7:TR?= NVLxUopZW0GQR1XS
LU-139 NXzxPVk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaTWM2OD1zOT6wOFU5KM7:TR?= MXfTRW5ITVJ?
ECC10 NYjXOFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF7LkK0O|Uh|ryP MlXIV2FPT0WU
769-P MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF7Lk[zN|Uh|ryP NH\oc2hUSU6JRWK=
BALL-1 M4PjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XaVGlEPTB;MUmuOlc4PSEQvF2= NXjCPXREW0GQR1XS
LXF-289 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF7Lki5O|kh|ryP MWXTRW5ITVJ?
TYK-nu MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljTTWM2OD1zOT65N|E2KM7:TR?= MWfTRW5ITVJ?
NCI-H630 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF7LkmzO|gh|ryP M1Kwe3NCVkeHUh?=
EW-18 NHPFbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f6eWlEPTB;MkCuN|gxOiEQvF2= MVvTRW5ITVJ?
KYSE-150 M2j6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\4eoNuUUN3ME2yNE44ODR5IN88US=> NILOdnlUSU6JRWK=
LOXIMVI MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW0TWM2OD1{MD63OVg3KM7:TR?= MVXTRW5ITVJ?
HuP-T3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\UTWM2OD1{MT6wPFUzKM7:TR?= M1P0eHNCVkeHUh?=
MFE-280 NIG5cZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TtV2lEPTB;MkGuOVY4QSEQvF2= M36zfHNCVkeHUh?=
SK-OV-3 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP0TWM2OD1{MT64OFA5KM7:TR?= MlXqV2FPT0WU
QIMR-WIL NV75VIc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ{LkC0O|gh|ryP M1W0PHNCVkeHUh?=
NCI-H69 NEL1doNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS0TWM2OD1{Mj60Nlk6KM7:TR?= NWTqemkxW0GQR1XS
TE-5 NUnU[IRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLWTWM2OD1{Mj60PVY2KM7:TR?= M3z2VnNCVkeHUh?=
NCI-H1993 NV3sfnFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPVfWdKSzVyPUKyMlQ6PzFizszN NX7ue3lIW0GQR1XS
NCI-H1092 NInFUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ|LkK4OFMh|ryP M1HDcHNCVkeHUh?=
RH-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fjSWlEPTB;MkOuOVM2PyEQvF2= NHTRRoxUSU6JRWK=
DBTRG-05MG MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ|Lki0O|Ih|ryP MofYV2FPT0WU
Mo-T MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjDNZZKSzVyPUKzMlkh|ryP MXfTRW5ITVJ?
HD-MY-Z MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ2LkKzOlIh|ryP MmjxV2FPT0WU
NCI-H2342 NHXWV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfLOJhnUUN3ME2yOE43PzZ5IN88US=> MmXXV2FPT0WU
C32 NUfVOFFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ2Lkm1O|Yh|ryP MlznV2FPT0WU
HTC-C3 M1zk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fZVWlEPTB;MkWuN|U4PyEQvF2= MnjIV2FPT0WU
NCI-H358 NHXRVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv2W3JKSzVyPUK1MlM6PDNizszN MlLnV2FPT0WU
CAL-85-1 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e5UmlEPTB;MkWuOFU4PyEQvF2= NI[1XIlUSU6JRWK=
HT-1197 NXTjZ5hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ3LkWzNVkh|ryP NUDNXpVNW0GQR1XS
A172 NIPzVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHJd|JKSzVyPUK1MlcyOzZizszN NEHIcohUSU6JRWK=
SW1573 M1XLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMNGlEPTB;MkWuO|c5PSEQvF2= NV;WXopbW0GQR1XS
EW-24 M1f3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q4bWlEPTB;MkWuPVYzKM7:TR?= NHjiUFhUSU6JRWK=
SK-MEL-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;rTWM2OD1{Nj6wN|EzKM7:TR?= Mlm0V2FPT0WU
LU-65 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ4LkC0OVIh|ryP MXjTRW5ITVJ?
KMOE-2 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\tUJpKSzVyPUK2MlA6OTVizszN NETKPYpUSU6JRWK=
H-EMC-SS NX;HVFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ4LkSxNVQh|ryP NVntcZI1W0GQR1XS
H4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pa[2lEPTB;Mk[uOFI1OyEQvF2= NIPRZnZUSU6JRWK=
DU-4475 M1\H[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHiRYFKSzVyPUK3MlE5PzJizszN NWXXRoxwW0GQR1XS
HCT-116 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvPS3VKSzVyPUK3MlQ{PDlizszN MkPEV2FPT0WU
MSTO-211H M1PqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3kTWM2OD1{Nz62NlU2KM7:TR?= Mn;rV2FPT0WU
NCI-H292 NXHldIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPFS|RLUUN3ME2yO{46PjF5IN88US=> M{T6fXNCVkeHUh?=
NCI-H446 NFnnRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvKbnVKSzVyPUK4MlIyODVizszN NGW1NotUSU6JRWK=
NCI-H2009 NF[wOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPKTWM2OD1{OT6xOFMyKM7:TR?= MWLTRW5ITVJ?
MHH-ES-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vTdGlEPTB;MkmuN|Y5PSEQvF2= MXLTRW5ITVJ?
TI-73 NHXEb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfzUGdKSzVyPUK5MlQxODFizszN NEPqUXBUSU6JRWK=
NCI-H2228 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETzR5hKSzVyPUK5MlQ2QCEQvF2= M{i5S3NCVkeHUh?=
MHH-PREB-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LuZWlEPTB;MkmuOVUxPSEQvF2= NFPofG5USU6JRWK=
ChaGo-K-1 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\yS5pKSzVyPUK5MlYxQTdizszN MVTTRW5ITVJ?
KY821 NH3MUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ7Lk[0N|Mh|ryP MmHHV2FPT0WU
NCI-H209 MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJ7LkizOlYh|ryP NVXnUVZwW0GQR1XS
NBsusSR MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3KfZBKSzVyPUK5Mlk6ODRizszN M{CxN3NCVkeHUh?=
NCI-H1304 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDnNm9KSzVyPUOwMlU4OTZizszN M1ridXNCVkeHUh?=
NB14 NIPaUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNzLkC0OFYh|ryP MXzTRW5ITVJ?
HCC1419 NGXBSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PqVmlEPTB;M{GuNlQh|ryP Mk\UV2FPT0WU
KG-1 NGnDRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGzNItKSzVyPUOxMlc1OjlizszN MYnTRW5ITVJ?
A2780 NVL4d2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzp[lM3UUN3ME2zNU45OzV6IN88US=> MVjTRW5ITVJ?
NCI-H28 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNzLkm4OlEh|ryP MkXqV2FPT0WU
C2BBe1 NF2yOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTN{LkK2N|Qh|ryP MXPTRW5ITVJ?
VA-ES-BJ M4jRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHVTWM2OD1|Mj6zNUDPxE1? NXG3XXJ4W0GQR1XS
SBC-5 NX;RWnRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT1TWM2OD1|Mj64OVEyKM7:TR?= MXvTRW5ITVJ?
OVCAR-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz5TWM2OD1|Mz60PFQ5KM7:TR?= MWTTRW5ITVJ?
COR-L88 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrwVZNKSzVyPUO0MlA4PDFizszN NVvOXXJXW0GQR1XS
SW954 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPGcoJKSzVyPUO0MlA4PTJizszN NXTqdnFpW0GQR1XS
COLO-684 M3nFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnsPJlKSzVyPUO0MlM1ODRizszN MmPEV2FPT0WU
HCC70 NILv[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17INGlEPTB;M{SuPVUyPCEQvF2= MXPTRW5ITVJ?
NCI-H1770 NEXke2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN2Lkm2NUDPxE1? NHHHT3ZUSU6JRWK=
NCI-H1666 M{DuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rVe2lEPTB;M{WuPFI2OyEQvF2= NVfFdVVlW0GQR1XS
YH-13 M{H6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjCd292UUN3ME2zOU46OiEQvF2= MXfTRW5ITVJ?
DJM-1 Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjzSYhKSzVyPUO2MlgxPDlizszN M1LSR3NCVkeHUh?=
KNS-62 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zGU2lEPTB;M{[uPVQ{QCEQvF2= Ml;SV2FPT0WU
SK-MEL-30 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LEeWlEPTB;M{euPFc{PyEQvF2= NYHxSmlMW0GQR1XS
SJRH30 MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXrbYF4UUN3ME2zPE44OzRzIN88US=> M{nuWXNCVkeHUh?=
GP5d NETrfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PWdmlEPTB;M{iuPFY2OyEQvF2= M1rqW3NCVkeHUh?=
SW1116 NX\FWHlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTYWmx3UUN3ME2zPU4zQDB3IN88US=> MnO0V2FPT0WU
COLO-800 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojaTWM2OD1|OT6zOlM5KM7:TR?= M1rTVXNCVkeHUh?=
RD MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\WTWM2OD1|OT61NlU5KM7:TR?= MkTlV2FPT0WU
NCI-SNU-5 Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL4TWM2OD1|OT62PVE3KM7:TR?= MYjTRW5ITVJ?
HuO-3N1 NXvGeY1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v2bmlEPTB;NECuNVA5KM7:TR?= NUnyfYZrW0GQR1XS
SK-UT-1 M1PzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImwRW9KSzVyPUSwMlU3PzRizszN M1;2b3NCVkeHUh?=
SK-MEL-3 NGHye2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRyLkW5N|Ih|ryP NH7aOWRUSU6JRWK=
SK-MEL-28 NVTuZ4ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnKXoVbUUN3ME20NE43PDN3IN88US=> MUDTRW5ITVJ?
SCC-4 M3H4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\I[GlEPTB;NEGuNlE{PyEQvF2= NEfR[4lUSU6JRWK=
no-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW5XYo3UUN3ME20NU44OzV2IN88US=> MYnTRW5ITVJ?
HT-144 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjZTWM2OD12Mj6wOVY4KM7:TR?= NITzTIdUSU6JRWK=
MFM-223 M3fKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TpdGlEPTB;NEKuOFAzKM7:TR?= NWjYbHFvW0GQR1XS
ONS-76 NV7rSJhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR{LkiwNVgh|ryP MVnTRW5ITVJ?
ES8 NIW5blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTR|LkO2PVgh|ryP M1rZ[3NCVkeHUh?=
T-24 M2rYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR|LkSzOlkh|ryP NEL5fVJUSU6JRWK=
GAMG NV7DNY1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fMTGlEPTB;NEOuOFUyPyEQvF2= NYe5eG5RW0GQR1XS
LU-135 NEXJNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTR2LkC5NlMh|ryP M4f4[3NCVkeHUh?=
HCC1187 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\LR3dKSzVyPUS0MlgzPjJizszN NUXse3BtW0GQR1XS
TE-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7JTWM2OD12NT6xOlU1KM7:TR?= M3rLTHNCVkeHUh?=
J-RT3-T3-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPod|RKSzVyPUS1MlQ{OTVizszN NFPIWZBUSU6JRWK=
GI-ME-N M13PSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjVOFg3UUN3ME20OU45QTV{IN88US=> NGLyVVRUSU6JRWK=
D-392MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnToTWM2OD12NT65NlU3KM7:TR?= MnuxV2FPT0WU
KALS-1 MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2iybmlEPTB;NE[uO|I2PyEQvF2= NXToPFNVW0GQR1XS
MMAC-SF NV3OVlRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XLVmlEPTB;NE[uPVk2OiEQvF2= NVzZSnNEW0GQR1XS
HSC-3 MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTR5LkO2NFgh|ryP NXTuV2dLW0GQR1XS
KM-H2 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPSUFFYUUN3ME20O{43ODB5IN88US=> MYDTRW5ITVJ?
LoVo MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTR6LkGwNFIh|ryP NFG1W|JUSU6JRWK=
NCI-H510A NYfXWXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz3cpJKSzVyPUS4MlE5PzFizszN M37adHNCVkeHUh?=
EW-11 M{nk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe0T2pKSzVyPUS4MlI{PDhizszN NXz3UVREW0GQR1XS
HCC2998 NXLTRWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\MVWlEPTB;NEiuOlI{PiEQvF2= MVfTRW5ITVJ?
J82 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnPTWM2OD12OD63NlQzKM7:TR?= MoDrV2FPT0WU
ML-2 NFfQ[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm2VpM2UUN3ME20PU41PjB3IN88US=> MXfTRW5ITVJ?
NCI-H2030 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTR7LkexNVch|ryP NWjjVGRSW0GQR1XS
NCI-H1792 NGD0U5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTR7Lki1NVgh|ryP MVHTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-AMPKα / AMPKα / p-AMPKβ1 / AMPKγ2 / p-LKB1 / LKB1 / CaMKIIβ ; 

PubMed: 23677989     


Dose-dependent analysis of AMPK-related molecules in HCC cells. Cells were exposed to nilotinib at the indicated concentrations for 24 h.

DNMT1 / DNMT3a / DNMT3b ; 

PubMed: 28720666     


Kasumi-1 or MV4-11 cells were treated for 24 h with the indicated doses of nilotinib and subjected western blot analysis to detect the expression levels of DNMT1, DNMT3a, DNMT3b.

pABL1 / p-NF-κB1 / NF-κB / STAT3 / p-STAT3 / IL-1β / IL-6 / COX2 ; 

PubMed: 31396300     


ABL1 regulated the inflammation signaling pathway. Blocking activities of ABL1 with Imatinib and Nilotinib inhibits the inflammatory signaling pathway including activities of NF-κB1, STAT3, IL-1β, IL-6, and COX2.

23677989 28720666 31396300
Growth inhibition assay
Cell viability; 

PubMed: 23677989     


Dose-dependent effects of nilotinib on cell viability. HCC cells were treated with nilotinib at the indicated concentrations for 72 h. Cell viability was measured by MTT assay. Points, mean; bars, S.D. (n = 8). 

23677989
体内試験 Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

お薦めの試験操作(参考用のみ)

細胞試験: [4]
- 合併
  • 細胞株: Human primary Schwann and schwannoma cells
  • 濃度: 1-10 μM
  • 反応時間: 72 hours
  • 実験の流れ: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (参考用のみ)
動物試験:[6]
- 合併
  • 動物モデル: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • 投薬量: 75 mg/kg, 100 mg/kg
  • 投与方法: Oral administration
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 529.52
化学式

C28H22F3N7O

CAS No. 641571-10-0
保管
in solvent
別名 N/A
Smiles CC1=C[N](C=N1)C2=CC(=CC(=C2)C(F)(F)F)NC(=O)C3=CC=C(C)C(=C3)NC4=NC=CC(=N4)C5=CN=CC=C5

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(余分な消耗を考慮し動物一匹分の量を用意することをお勧めします。)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロットごとに組成が異なるため、セレックから完全に溶解できる組成をお求めください。)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04326933 Not yet recruiting Drug: Tyrosine kinase Inhibitors (Imatinib & Nilotinib) Patients Diagnosed as Chronic Meyloid Leukemia Assiut University October 20 2020 --
NCT03942094 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Chronic Phase|Nilotinib Shenzhen Second People''s Hospital June 1 2019 Phase 3
NCT03874858 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT04002674 Active not recruiting Drug: Placebo oral capsule|Drug: Nilotinib Oral Capsule Dementia With Lewy Bodies Georgetown University|National Institutes of Health (NIH) January 14 2019 Phase 2
NCT02973711 Suspended Drug: Nilotinib|Drug: Ruxolitinib Leukemia Chronic Myeloid University of Michigan Rogel Cancer Center January 18 2018 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • 回答:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Ablシグナル伝達経路

Bcr-Abl Inhibitors with Unique Features

相関Bcr-Abl製品

Tags: Nilotinib (AMN-107)を買う | Nilotinib (AMN-107) ic50 | Nilotinib (AMN-107)供給者 | Nilotinib (AMN-107)を購入する | Nilotinib (AMN-107)費用 | Nilotinib (AMN-107)生産者 | オーダーNilotinib (AMN-107) | Nilotinib (AMN-107)化学構造 | Nilotinib (AMN-107)分子量 | Nilotinib (AMN-107)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID